CClinicalTrials.gg
CompletedNCT06181214Updated Mar 22, 2024

The Effects of a Novel Nutritional Product on Nutrient Status and Digestive Health

An interventional study of AG1 - Nutritional Supplement and Placebo in Gastrointestinal Microbiome, Nutrition, Healthy and Healthy Aging, sponsored by Athletic Greens International. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Athletic Greens International · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2023, registered Dec 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, placebo-controlled study of N=30 apparently healthy men and women. This is an exploratory study to assess the effect of a novel dietary supplement on blood markers of nutrient status and the gut microbiome.

02

Conditions studied

  • Gastrointestinal Microbiome
  • Nutrition, Healthy
  • Healthy Aging
03

In context

Lead sponsor

Athletic Greens International is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Provide voluntary signed and dated informed consent.
  • Be in good health as determined by medical history and routine blood chemistries.
  • Age between 18 and 50 yr (inclusive).
  • Body Mass Index of 18.5-29.9 (inclusive).
  • Body weight of at least 120 pounds.
  • Normotensive (seated, resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
  • Normal seated, resting heart rate (\<90 per minute).
  • Willing to duplicate their previous 24-hour diet, refrain from caffeine and exercise for 24 hours prior to each visit, and fast for 10 hours prior to each visit.
  • Subject agrees to maintain existing dietary and physical activity patterns throughout the study period.
  • Subject is willing and able to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • History of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal conditions.
  • History of diabetes or endocrine disorder.
  • History of use of medications or dietary supplements known to confound the study or its endpoints.
  • Alcohol consumption (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence within the past 6 months.
  • Current smokers or smoking within the past month.
  • History of hyperparathyroidism or an untreated thyroid condition.
  • History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
  • Prior gastrointestinal bypass surgery (Lapband), etc.
  • Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, Irritable bowel syndrome (IBS), diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
  • Chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.).
  • Previous medical diagnosis of asthma, gout, or fibromyalgia.
  • Pregnant women, women trying to become pregnant, women less than 120 days postpartum or nursing women. Women who participate in this study must agree to the use of contraception for the duration of the study and any woman that is sexually active will have to take a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause) regardless of their use of contraception will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent.
  • Known sensitivity to any ingredient in the test formulations as listed in the product label.
  • Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
  • Any other conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Maltodextrin + Flavoring

    Dietary Supplement: Placebo

  • Experimental
    AG1 - Nutritional Supplement

    A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients

    Dietary Supplement: AG1 - Nutritional Supplement

Interventions

  • Dietary supplementAG1 - Nutritional Supplement

    A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients

  • Dietary supplementPlacebo

    Maltodextrin placebo

06

What researchers measure

Primary outcomes

  1. Gut Microbiome

    Examine changes in the gut microbiome structure and function measured by shallow shotgun metagenomics. Examine enrichment of taxa and metabolic pathways in the gut microbiome as a result of dietary supplementation.

    Time frame: 28 days

Secondary outcomes

  1. Complete Metabolic Blood Panel

    Serum concentrations of sodium, potassium, carbon dioxide, chloride, albumin, total protein, glucose, and calcium., ALT, AST, bilirubin, BUN, creatinine

    Time frame: 28 Days

  2. Complete Blood Count

    Circulating concentrations of white blood cells, red blood cells, hemoglobin, and hematocrit

    Time frame: 28 Days

  3. Exploratory nutrient status markers

    Circulating concentrations of nutrient status (e.gg, zinc, vitamin c, folate, \& magnesium)

    Time frame: 28 days

  4. Exploratory Digestive Measures

    A Digestive Quality of Life Questionnaire (DQLQ) will be utilized to assess the effect of the interventions on participant's digestive health. Scores range from 0 to 9 with a higher score indicating worse digestion associated with quality of life

    Time frame: 28 days

  5. Exploratory Stool Consistency

    Bristol Stool Scale (score 1-7) questionnaire that allows participants to identify how loose or hard their stool consistency is

    Time frame: 28 days

  6. Exploratory Stool Frequency

    100mm Visual Analog Scale (VAS) to assess subjective ratings of stool consistency and frequency of bowl movements

    Time frame: 28 days

07

Study locations

1 site
  • Center for Applied Health Sciences
    Canfield, Ohio 44046, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06181214
Lead sponsor
Athletic Greens International
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Aug 14, 2023
Primary completion
Oct 4, 2023
Completion
Oct 4, 2023
Last update
Mar 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion